Ignite Creation Date:
2024-05-06 @ 2:20 PM
Last Modification Date:
2024-10-26 @ 1:29 PM
Study NCT ID:
NCT04286815
Status:
RECRUITING
Last Update Posted:
2020-03-27
First Post:
2020-02-23
Brief Title:
Gene Therapy for X Linked Severe Combined Immunodeficiency
Sponsor:
Childrens Hospital of Chongqing Medical University
Organization:
Childrens Hospital of Chongqing Medical University
Study Overview
Official Title:
Gene Therapy for X Linked Severe Combined Immunodeficiency
Status:
RECRUITING
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A safety and efficacy clinical study of a lentiviral vector to transfer IL2RG complementary DNA to bone marrow stem cells in ten children with genetic diagnosed X-SCIDsevere combined immune deficiency The ten children will be followed for 3-5 years and be evaluated by clinical characteristics vector marking vector copy number per cell in blood and bone marrow cells immune reconstitution vector insertion-site patterns and so on
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None